Insmed (INSM) Liabilities and Shareholders Equity (2011 - 2026)
Insmed (INSM) posted quarterly Liabilities and Shareholders Equity of $2.1 billion for Q1 2026, up 15.15% year-over-year from $1.8 billion in Q1 2025, and down 8.33% quarter-over-quarter from $2.3 billion in Q4 2025.
Insmed (INSM) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Insmed's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $2.1 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 15.15% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $9.2 billion (up 19.37% YoY), while the FY2025 annual figure was $2.3 billion, up 11.82% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $2.1 billion, down from $2.3 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $2.5 billion in Q2 2025, with the low at $994.8 million in Q3 2022.
- The 5-year median for Liabilities and Shareholders Equity is $1.7 billion (2022), against an average of $1.7 billion.
- Peak annual rise in Liabilities and Shareholders Equity reached 66.57% in 2022, while the deepest fall reached 24.16% in 2022.
- Insmed's Liabilities and Shareholders Equity stood at $1.7 billion in 2022, then fell by 19.72% to $1.3 billion in 2023, then jumped by 52.29% to $2.0 billion in 2024, then advanced by 11.82% to $2.3 billion in 2025, then dropped by 8.33% to $2.1 billion in 2026.
- Business Quant data shows INSM's Liabilities and Shareholders Equity at $2.1 billion in Q1 2026, $2.3 billion in Q4 2025, and $2.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.10 Bn |
| Mar 31, 2026 | 2.08 Bn |
| Dec 31, 2025 | 2.26 Bn |
| Sep 30, 2025 | 2.36 Bn |
| Jun 30, 2025 | 2.48 Bn |
| Mar 31, 2025 | 1.80 Bn |
| Dec 31, 2024 | 2.03 Bn |
| Sep 30, 2024 | 2.05 Bn |
| Jun 30, 2024 | 1.81 Bn |
| Mar 31, 2024 | 1.16 Bn |
| Dec 31, 2023 | 1.33 Bn |
| Sep 30, 2023 | 1.32 Bn |
| Jun 30, 2023 | 1.44 Bn |
| Mar 31, 2023 | 1.52 Bn |
| Dec 31, 2022 | 1.66 Bn |
| Sep 30, 2022 | 994.82 Mn |
| Jun 30, 2022 | 1.05 Bn |
| Mar 31, 2022 | 1.15 Bn |
| Dec 31, 2021 | 1.24 Bn |
| Sep 30, 2021 | 1.31 Bn |